Scientists at Chungnam National University assessed the role of estrogen-related receptor α (ERRα) in the context of acute myeloid leukemia (AML). First, it was demonstrated that ERRα expression levels were increased in bone marrow of patients with AML as compared to normal control patients, and that patient survival was significantly correlated with ERRα expression.
Day One Biopharmaceuticals Inc. has entered into an exclusive licensing agreement with Mabcare Therapeutics for MTX-13, a novel antibody-drug conjugate (ADC) targeting protein-tyrosine kinase 7 (PTK7). Under the agreement, Day One has exclusive rights to develop, manufacture and commercialize MTX-13 (now DAY-301), worldwide, excluding Greater China.
Aberrant overactivity of platelets may lead to the formation of occlusive thrombi and consequently lead to myocardial infarction or stroke. At the recent EHA meeting, researchers from the University of Michigan and Cereno Scientific AB presented data regarding their prostacyclin (IP) receptor agonist CS-585 as a thrombolytic.
Italfarmaco SpA and Iktos SA have entered into a collaboration to develop next-generation histone deacetylase (HDAC) inhibitors for a variety of non-oncological diseases, including diseases affecting the central nervous system.
Lhotse Bio Inc. has described lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of cancer, fibrosis, inflammatory disorders, multiple sclerosis, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly nonalcoholic fatty liver disease [NAFLD]), osteoporosis, SARS-CoV-2 infection (COVID-19) and transplant rejection.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has synthesized cyclin-dependent kinase 8 (CDK8) and/or CDK19 inhibitors reported to be useful for the treatment of cancer.
Daegu-Gyeongbuk Medical Innovation Foundation has disclosed estrogen receptor α (ER-α; ESR1) antagonists reported to be useful for the treatment of cancer.
Researchers from Philochem AG recently reported the discovered OncoFAP, a high-affinity small organic ligand of fibroblast activation protein (FAP) that has shown rapid accumulation in tumors and low uptake in healthy tissues in preclinical models.
RSS
